Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Pharma

AZT-01

Eczema (atopic dermatitis), ichthyosis vulgaris

Preclinical | $8 B US Market

AZT-01 is a proprietary strain of Staphylococcus epidermidis, a bacterium naturally found in the skin microbiome. Our strain is engineered to express therapeutic levels of filaggrin protein. Filaggrin, a natural skin protein essential to the maintenance of a strong skin barrier, is often deficient in patients with atopic dermatitis (eczema). AZT-01 will be applied topically and is being designed to correct dysbiosis (an imbalance in the microbiome) in the skin, reduce inflammation, and improve skin barrier function.

Pharma

AZT-02

Netherton Syndrome (Orphan)

Discovery | $300 M US Market

AZT-02 is a proprietary strain of Staphylococcus epidermidis, a bacterium naturally found in the skin microbiome, engineered to express therapeutic levels of LEKTI protein. LEKTI is a protease inhibitor essential to maintaining skin structure, and is missing in patients suffering from Netherton syndrome (NS), a severely disabling orphan condition. AZT-02 will be applied topically and is being designed to provide continual replacement of the missing LEKTI protein to improve the skin structure and quality of life of NS patients.

Consumer Health

AZT-04

Rough, dry skin

Preclinical | >$10 B US Market

AZT-04 is a proprietary strain of Staphylococcus epidermidis (S. epi.), a bacterium naturally found in the skin microbiome, formulated for use in consumer health. Azitra created an auxotroph of this strain of S. epi. for application to the skin. AZT-04 is expected to establish a more natural microbial balance on the skin. Firmer, smoother, and moister skin are among the benefits expected with use of AZT-04.